Fierce Pharma Biopharma News Insights Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance
News | PharmExec In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi enters a $2 billion agreement to acquire rights to Radicava, and the FTC examines antitrust concerns tied to CVS Health’s integrated healthcare model
Biotech and Pharma Industry News | BioPharma Dive BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more
Pharmaceuticals sector - Financial Times Comprehensive coverage of the pharmaceuticals industry The latest news and developments from the world's leading drug companies, including Pfizer, Johnson Johnson, AstraZeneca and more
Pharma, Biotech and Generics Industry News | The Pharmaletter Pharma, Biotech and Generics Industry News Over the past year, the US Food and Drug Administration (FDA) has increased enforcement activity related to compounded medications that are similar to commercially available products 1 One area where this is especially visible is GLP-1 receptor agonists used for diabetes and weight management High demand for these therapies has, at times, outpaced
Healthcare Pharmaceutical Healthcare Pharmaceutical Biotech Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place
Pharma Sector News | PharmaVoice Novartis’ acquisition of Excellergy for up to $2 billion portends a potential new wave of medicines for food allergies The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry